Neovascular Age-Related Macular Degeneration
Conditions
Brief summary
Phase 1: The purpose of this study is to evaluate the safety and tolerability of single ascending doses of hI-con1™ for subjects with Age-Related Macular Degeneration. Phase 2: The purpose of this study is to evaluate the safety of 3 injections of hI-con1™ at 2 different dose levels.
Interventions
DRUGhI-con1™ 60µl
Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
DRUGhI-con1™ 150µl
Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
DRUGhI-con1™ 300µl
Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
Sponsors
Iconic Therapeutics, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Ocular Inclusion Criteria: * Active choroidal neovascularization (CNV) associated with age-related macular degeneration, as evidenced on fluorescein angiography (FA) and Optical Coherence Tomography (OCT), with the following lesion characteristics: * Subretinal hemorrhage if present \< 50% of total lesion size * During Phase 1, the 4th, 5th, and 6th subjects enrolled in each cohort must have total lesion area \< 6 Disc Area (DA) (total area of detachment) (15.24 mm2), of which at least 50% must be actively leaking, and 30% should be classic on the angiography as determined by a reading center, and no more than 3 prior injections of any therapy for the treatment of CNV. * For Phase 2, total lesion area \< 6 DA (total area of detachment) (15.24 mm2), of which at least 50% must be actively leaking, and 30% should be classic on the angiography as determined by a reading center and no more than 3 prior injections of any therapy for the treatment of CNV. * Best Corrected Visual Acuity (BCVA) for Phase 1: 20/ 80 - count fingers in the study eye; visual acuity in the fellow eye must be the same or better than the study eye * BCVA for Phase 2: 20/40 to 20/320 in the study eye; visual acuity in the fellow eye must be the same or better than the study eye * Only one eye of each subject will be treated in the study. If both eyes are eligible, the study eye will be the eye with the worst visual acuity. If visual acuity is the same in both eyes, the eye with the most active CNV will be selected to be the study eye * Clear ocular media and adequate pupillary dilation in the study eye to permit fundus photography for screening * Intraocular pressure of 21 mm Hg or less in the study eye. General Inclusion Criteria * Subjects of either gender, \> 50 years of age * Subjects who are informed of, and willing and able to comply with, the investigational nature of the study and are able to provide written informed consent * Ability to return for all study visits * Females must be of non-child bearing potential (surgically sterilized or at least 2 years post-menopausal) or if of child-bearing potential, the subject must have a negative serum pregnancy test within 14 days prior to the first injection and agree to use 2 forms of effective contraception during the trial and for at least 60 days following the last study injection. Ocular
Exclusion criteria
* Any retinal vascular disease or retinal degeneration other than AMD in the study eye * Serous pigment epithelial detachment without the presence of choroidal neovascularization in the study eye * Pigment epithelial tears or rips in the study eye * Previous posterior vitrectomy or retinal surgery in the study eye * Any periocular infection in the past 4 weeks in the study eye * During the duration of the study, subjects cannot be on any concomitant therapy with anti-VEGF (Vascular Endothelial Growth Factor) agents, e.g., Lucentis® , Avastin®, or Macugen® in the study eye (unless identified as rescue therapy given according to protocol guidelines) * Concomitant therapy or use within 30 days of Baseline (Day 1) of systemic (e.g. intravenous, oral, intramuscular, rectal) corticosteroids in doses \> 10 mg/ day prednisone or prednisone equivalent, or use of intravitreous or periocular steroids within 90 days of Baseline (Day 1) in the study eye * Any current or prior use of extended-release steroid implants (e.g., Retisert®, Posurdex®, Medidur®) in the study eye * Significant media opacities, including cataract, in the study eye which might interfere with visual acuity, assessment of toxicity, or fundus photography. * Cataract surgery in the study eye within three months of screening * Trabeculectomy or outflow-device glaucoma surgery in the study eye * Intraocular surgery in the study eye within three months of screening * Periocular or ocular infection in the study eye * Severe myopia (spherical equivalent -8 diopters or greater) in the study eye * History of vascular pigment epithelial detachment or submacular hemorrhage in the fellow eye. General
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Change in Central Retinal Subfield Thickness as Measured by Optical Coherence Tomography (OCT) at Week 24 From Baseline | 24 Weeks | The Mean Change in Central Retinal Subfield Thickness as Measured by OCT is part of the evaluation on the safety and tolerability of single ascending doses of hI-con1 and to assist in determining the Maximum Tolerated Dose (MTD) that can be administered by intravitreal injection. |
| Mean Change in Best Corrected Visual Acuity (BCVA) at Week 24 From Baseline | 24 Weeks | The Mean Change in Best Corrected Visual Acuity (BCVA) is part of the evaluation on the safety and tolerability of single ascending doses of hI-con1 and to assist in determining the Maximum Tolerated Dose (MTD) that can be administered by intravitreal injection. BCVA is measured using the Early Diabetic Retinopathy Study (EDTRS) chart. More letters read result in a higher score. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| hI-con1™ 60µg This is a dose escalation study 60µg, 150µg, or 300 µg) given at baseline and then the subject is followed up to week 24. | 6 |
| hI-con1™ 150µg This is a dose escalation study 60µg, 150µg, or 300 µg) given at baseline and then the subject is followed up to week 24. | 6 |
| hI-con1™ 300µg This is a dose escalation study 60µg, 150µg, or 300 µg) given at baseline and then the subject is followed up to week 24. | 6 |
| Total | 18 |
Baseline characteristics
| Characteristic | hI-con1™ 60µg | hI-con1™ 150µg | hI-con1™ 300µg | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 6 Participants | 6 Participants | 6 Participants | 18 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Region of Enrollment United States | 6 participants | 6 participants | 6 participants | 18 participants |
| Sex: Female, Male Female | 1 Participants | 3 Participants | 4 Participants | 8 Participants |
| Sex: Female, Male Male | 5 Participants | 3 Participants | 2 Participants | 10 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 6 | 0 / 6 | 0 / 6 |
| other Total, other adverse events | 6 / 6 | 6 / 6 | 6 / 6 |
| serious Total, serious adverse events | 0 / 6 | 0 / 6 | 1 / 6 |
Outcome results
Primary
Mean Change in Best Corrected Visual Acuity (BCVA) at Week 24 From Baseline
The Mean Change in Best Corrected Visual Acuity (BCVA) is part of the evaluation on the safety and tolerability of single ascending doses of hI-con1 and to assist in determining the Maximum Tolerated Dose (MTD) that can be administered by intravitreal injection. BCVA is measured using the Early Diabetic Retinopathy Study (EDTRS) chart. More letters read result in a higher score.
Time frame: 24 Weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| hI-con1™ 60µg | Mean Change in Best Corrected Visual Acuity (BCVA) at Week 24 From Baseline | -9.3 Letters | Standard Deviation 6.81 |
| hI-con1™ 150µg | Mean Change in Best Corrected Visual Acuity (BCVA) at Week 24 From Baseline | 6.0 Letters | Standard Deviation 1 |
| hI-con1™ 300µg | Mean Change in Best Corrected Visual Acuity (BCVA) at Week 24 From Baseline | 15.7 Letters | Standard Deviation 5.03 |
Primary
Mean Change in Central Retinal Subfield Thickness as Measured by Optical Coherence Tomography (OCT) at Week 24 From Baseline
The Mean Change in Central Retinal Subfield Thickness as Measured by OCT is part of the evaluation on the safety and tolerability of single ascending doses of hI-con1 and to assist in determining the Maximum Tolerated Dose (MTD) that can be administered by intravitreal injection.
Time frame: 24 Weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| hI-con1™ 60µg | Mean Change in Central Retinal Subfield Thickness as Measured by Optical Coherence Tomography (OCT) at Week 24 From Baseline | -98 Microns | Standard Deviation 141.19 |
| hI-con1™ 150µg | Mean Change in Central Retinal Subfield Thickness as Measured by Optical Coherence Tomography (OCT) at Week 24 From Baseline | -66 Microns | Standard Deviation 42.03 |
| hI-con1™ 300µg | Mean Change in Central Retinal Subfield Thickness as Measured by Optical Coherence Tomography (OCT) at Week 24 From Baseline | -180.8 Microns | Standard Deviation 97.9 |